medigraphic.com
Instituto Nacional de Salud Pública

2022, Número 4

<< Anterior Siguiente >>

salud publica mex 2022; 64 (4)


Prevalencia de anticuerpos contra SARS-CoV-2 y factores asociados en trabajadores de la salud de un hospital Covid-19 en México

Herrera-Ortiz A, Rojas-Delgado HU, García-Cisneros S, Xibille-Friedmann DX, Martínez-Barnetche J, Olamendi-Portugal M, González-Sánchez HM, Sánchez-Alemán MÁ

Idioma: Ingles.
Referencias bibliográficas: 37
Paginas: 348-356
Archivo PDF: 268.48 Kb.


RESUMEN

Objetivo. Determinar la prevalencia de anticuerpos contra SARS-CoV-2 entre trabajadores de la salud e identificar factores asociados con la infección. Material y métodos. Se realizó un estudio transversal en un hospital Covid-19 de Morelos. Se detectaron anticuerpos contra las proteínas spike y nucleocápside del SARS-CoV-2 por ELISA. Se realizó un análisis bivariado y multivarible mediante regresión de Poisson para identificar factores asociados con la infección. Resultados. El 31% de los participantes tenía anticuerpos anti-SARS-CoV-2 y sólo 13.1% reportó antecedentes de RTPCR positiva. Cohabitar con una persona con Covid-19 y reportar una prueba RT-PCR fueron factores asociados con la seropositividad. El personal de laboratorios tuvo la prevalencia más baja (12.0%), mientras que trabajadores sociales la mayor (35.7%). Conclusiones. Se informa la seroprevalencia de anticuerpos contra SARS-CoV-2 entre personal de salud en un hospital de México y se subraya la importancia de las pruebas serológicas para una mejor estimación de la prevalencia en sistemas de salud que sólo registran casos sintomáticos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2): an update. Cureus. 2020;12(3):e7423.https://doi.org/10.7759/cureus.7423

  2. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamicsin viral shedding and transmissibility of COVID-19. Nat Med.2020;26(5):672-5. https://doi.org/10.1038/s41591-020-0869-5

  3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factorsfor mortality of adult inpatients with COVID-19 in Wuhan, China: aretrospective cohort study. Lancet. 2020;395(10229):1054-62. https://doi.org/10.1016/S0140-6736(20)30566-3

  4. Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, et al.Feasibility of controlling COVID-19 outbreaks by isolation of cases andcontacts. Lancet Glob Health. 2020;8(4):e488-96. https://doi.org/10.1016/S2214-109X(20)30074-7

  5. Li W, Su YY, Zhi SS, Huang J, Zhuang CL, Bai WZ, et al. Virus sheddingdynamics in asymptomatic and mildly symptomatic patients infected withSARS-CoV-2. Clin Microbiol Infect. 2020;26(11):1556.e1-6. https://doi.org/10.1016/j.cmi.2020.07.008

  6. Alserehi HA, Alqunaibet AM, Al-Tawfiq JA, Alharbi NK, Alshukairi AN,Alanazi KH, et al. Seroprevalence of SARS-CoV-2 (COVID-19) amonghealthcare workers in Saudi Arabia: comparing case and control hospitals.Diagn Microbiol Infect Dis. 2021;99(3):115273. https://doi.org/10.1016/j.diagmicrobio.2020.115273

  7. Piccoli L, Ferrari P, Piumatti G, Jovic S, Rodriguez BF, Mele F, et al. Riskassessment and seroprevalence of SARS-CoV-2 infection in healthcareworkers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland.Lancet Reg Health Eur. 2021;1:100013. https://doi.org/10.1016/j.lanepe.2020.100013

  8. ONU México. Uno de cada siete infectados de coronavirus es un trabajadormédico. México: Noticias ONU, 2020 [cited 2021 May 30]. Availablefrom: https://coronavirus.onu.org.mx/uno-de-cada-siete-infectados-decoronavirus-es-un-trabajador-medico

  9. Gomez-Ochoa SA, Franco OH, Rojas LZ, Raguindin PF, Roa-Diaz ZM,Wyssmann BM, et al. COVID-19 in healthcare workers: a living systematicreview and meta-analysis of prevalence, risk factors, clinical characteristics,and outcomes. Am J Epidemiol. 2021;190(1):161-75. https://doi.org/10.1093/aje/kwaa191

  10. Nakamura A, Sato R, Ando S, Oana N, Nozaki E, Endo H, et al. Orthogonalantibody testing for COVID-19 among healthcare workers in anon-epidemic place and time: Japan’s Iwate Prefecture, May 18-31, 2020.Fukushima J Med Sci. 2021;67(1):27-32. https://doi.org/10.5387/fms.2020-21

  11. Grant JJ, Wilmore SMS, McCann NS, Donnelly O, Lai RWL, Kinsella MJ,et al. Seroprevalence of SARS-CoV-2 antibodies in healthcare workers ata London NHS Trust. Infect Control Hosp Epidemiol. 2021;42(2):212-4.https://doi.org/10.1017/ice.2020.402

  12. Leeds C. COVID 19: Health care workers, risks, protection and transmission.Lancet Reg Health Eur. 2021;1:100022. https://doi.org/10.1016/j.lanepe.2020.100022

  13. Kalimuddin S, Tham CYL, Qui M, de Alwis R, Sim JXY, Lim JME, etal. Early T cell and binding antibody responses are associated withCOVID-19 RNA vaccine efficacy onset. Med (N Y). 2021;2(6):682.e4-8.https://doi.org/10.1016/j.medj.2021.04.003

  14. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence ofSARS-CoV-2 antibodies and associated factors in healthcare workers:a systematic review and meta-analysis. J Hosp Infect. 2021;108:120-34.https://doi.org/10.1016/j.jhin.2020.11.008

  15. Self WH, Tenforde MW, Stubblefield WB, Feldstein LR, Steingrub JS,Shapiro NI, et al. Seroprevalence of SARS-CoV-2 Among Frontline HealthCare Personnel in a Multistate Hospital Network - 13 Academic MedicalCenters, April-June 2020. Morb Mortal Wkly Rep. 2020;69(35):1221-6.https://doi.org/10.15585/mmwr.mm6935e2

  16. Venugopal U, Jilani N, Rabah S, Shariff MA, Jawed M, Mendez-Batres A, etal. SARS-CoV-2 seroprevalence among health care workers in a New YorkCity hospital: A cross-sectional analysis during the COVID-19 pandemic.Int J Infect Dis. 2021;102:63-9. https://doi.org/10.1016/j.ijid.2020.10.036

  17. Yogo N, Greenwood KL, Thompson L, Wells PJ, Munday S, Smith TC, etal. Point prevalence survey to evaluate the seropositivity for coronavirusdisease 2019 (COVID-19) among high-risk healthcare workers. InfectControl Hosp Epidemiol. 2021;42(10):1260-5. https://doi.org/10.1017/ice.2020.1370

  18. Costa SF, Giavina-Bianchi P, Buss L, Mesquita-Peres CH, Rafael MM, DosSantos LGN, et al. SARS-CoV-2 seroprevalence and risk factors amongoligo/asymptomatic healthcare workers (HCW): estimating the impact ofcommunity transmission. Clin Infect Dis. 2021;73(5):e1214-8. https://doi.org/10.1093/cid/ciaa1845

  19. Silva A, Aguirre M, Ballejo C, Marro M, Gamarnik A, Vargas G, et al.Seroprevalencia de Infección por SARS-COV-2 en personal de salud dela Región Sanitaria VIII, Provincia de Buenos Aires, Argentina. Rev ArgentSalud Publica. 2020;12(supl 1):1-9. Available from: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S1853-810X2020000300014&lng=es

  20. Ariza B, Torres X, Salgado D, Cepeda M, Restrepo CG, Castellanos JC,et al. Seroprevalence and seroconversion rates to SARS-CoV-2 in interns,residents, and medical doctors in a University Hospital in Bogotá, Colombia.Infectio. 2021;25(3):145-52. https://doi.org/10.22354/in.v25i3.938

  21. Chafloque-Vásquez RA, Pampa-Espinoza L, Celis-Salinas JC. Seroprevalenciade COVID-19 en trabajadores de un hospital de la Amazoníaperuana. Act Med Peru. 2020;37(3):390-2. https://doi.org/10.35663/amp.2020.373.1050

  22. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus Pandemic (COVID-19). Our World In Data[cited 2021 Jan]. Available from: https://ourworldindata.org/coronavirus

  23. Basto-Abreu A, Carnalla M, Torres-Ibarra L, Romero-Martínez M,Martínez-Barnetche J, et al. Nationally representative SARS-CoV-2 antibodyprevalence estimates after the first epidemic wave in Mexico. NatCommun. 2022;13(1):589. https://doi.org/10.1038/s41467-022-28232-9

  24. Goldblatt D, Johnson M, Falup-Pecurariu O, Ivaskeviciene I, Spoulou V,Tamm E, et al. Cross-sectional prevalence of SARS-CoV-2 antibodies inhealthcare workers in paediatric facilities in eight countries. J Hosp Infect.2021;110:60-6. https://doi.org/10.1016/j.jhin.2020.12.019

  25. Mahto M, Banerjee A, Biswas B, Kumar S, Agarwal N, Singh PK. Seroprevalenceof IgG against SARS-CoV-2 and its determinants among healthcareworkers of a COVID-19 dedicated hospital of India. Am J Blood Res.2021;11(1):44-52 [cited 2021 Jan]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010601/#__ffn_sectitle

  26. Kassem AM, Talaat H, Shawky S, Fouad R, Amer K, Elnagdy T, et al.SARS-CoV-2 infection among healthcare workers of a gastroenterologicalservice in a tertiary care facility. Arab J Gastroenterol. 2020;21(3):151-5.https://doi.org/10.1016/j.ajg.2020.07.005

  27. Kantele A, Lääveri T, Kareinen L, Pakkanen SH, Blomgren K, MeroS, et al. SARS-CoV-2 infections among healthcare workers at HelsinkiUniversity Hospital, Finland, spring 2020: Serosurvey, symptoms and riskfactors. Travel Med Infect Dis. 2021;39:101949. https://doi.org/10.1016/j.tmaid.2020.101949

  28. Galán MI, Velasco M, Casas ML, Goyanes MJ, Rodríguez-Caravaca G,Losa-García JE, et al. Hospital-Wide SARS-CoV-2 seroprevalence in healthcare workers in a Spanish teaching hospital. Enferm Infecc Microbiol Clin(Engl Ed). 2020;40(6):302-9. https://doi.org/10.1016/j.eimc.2020.11.015

  29. Barallat J, Fernández-Rivas G, Quirant-Sánchez B, González V, DoladéM, Martinez-Caceres E, et al. Seroprevalence of SARS-CoV-2 IgG specificantibodies among healthcare workers in the Northern MetropolitanArea of Barcelona, Spain, after the first pandemic wave. PLoS ONE.2020;15(12):e0244348. https://doi.org/10.1371/journal.pone.0244348

  30. Iversen K, Bundgaard H, Hasselbalch RB, Kristensen JH, Nielsen PB,Pries-Heje M, et al. Risk of COVID-19 in health-care workers in Denmark:an observational cohort study. Lancet Infect Dis. 2020;20(12):1401-8.https://doi.org/10.1016/S1473-3099(20)30589-2

  31. Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, et al. Antibody detectionand dynamic characteristics in patients with coronavirus disease 2019. ClinInfect Dis. 2020;71(8):1930-4. https://doi.org/10.1093/cid/ciaa461

  32. Masiá M, Telenti G, Fernández M, García JA, Agulló V, Padilla S, et al.SARS-CoV-2 seroconversion and viral clearance in patients hospitalizedwith COVID-19: viral load predicts antibody response. Open Forum InfectDis. 2021;8(2):ofab005. https://doi.org/10.1093/ofid/ofab005

  33. Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, et al. Kinetics of viralload and antibody response in relation to COVID-19 severity. J Clin Invest.2020;130(10):5235-44. https://doi.org/10.1172/JCI138759

  34. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responsesto SARS-CoV-2 in patients with novel coronavirus disease 2019. ClinInfect Dis. 2020;71(16):2027-34. https://doi.org/10.1093/cid/ciaa344

  35. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical andimmunological assessment of asymptomatic SARS-CoV-2 infections. NatMed. 2020;26(8):1200-4. https://doi.org/10.1038/s41591-020-0965-6

  36. Lumley SF, Wei J, O’Donnell D, Stoesser NE, Matthews PC, Howarth A,et al. The duration, dynamics, and determinants of severe acute respiratorysyndrome coronavirus 2 (SARS-CoV-2) antibody responses in individualhealthcare workers. Clin Infect Dis. 2021;73(3):e699-709. https://doi.org/10.1093/cid/ciab004

  37. Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, HatchSB, et al. Antibody status and incidence of SARS-CoV-2 infection in healthcare workers. N Engl J Med. 2021;384(6):533-40. https://doi.org/10.1056/NEJMoa2034545




2020     |     www.medigraphic.com